- Home
- GSBC vs ITRM Comparison
GSBC vs ITRM Comparison
Compare GSBC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSBC | ITRM |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.5M | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GSBC | ITRM |
|---|---|---|
| Price | $64.87 | $0.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $59.50 | $9.00 |
| AVG Volume (30 Days) | 56.2K | ★ 731.7K |
| Earning Date | 01-20-2026 | 02-06-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ 18.31 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $228,683,000.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $325.95 |
| P/E Ratio | $11.04 | ★ N/A |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $47.58 | $0.36 |
| 52 Week High | $66.59 | $2.10 |
Technical Indicators
Market Signals| Indicator | GSBC | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 33.80 |
| Support Level | $65.08 | $0.37 |
| Resistance Level | $66.59 | $0.49 |
| Average True Range (ATR) | 1.19 | 0.04 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 66.44 | 5.12 |
Price Performance
Historical ComparisonAbout GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.